Der er rapporteret en øget risiko for muskelrelaterede uønskede hændelser, inklusive rhabdomyolyse, hvis fibrater administreres sammen med andre statiner.
An increased risk of muscle related adverse events, including rhabdomyolysis, have been reported when fibrates are co- administered with other statins.